Doxycycline for the Reduction of Epistaxis in Hereditary Hemorrhagic Telangiectasia (DOXY HHT Trial)

Study Description

Doxycycline is an FDA approved antibiotic used to treat certain infections of the lungs and respiratory tract, skin, eye, and urinary tract. In addition to its use as an antibiotic, doxycycline also has the ability to prevent the development of new blood vessels and bleeding. Because of this effect, we want to see if doxycycline will help reduce the nosebleeds caused by HHT.

Study procedures

- Participants that agree to the study procedures and sign an informed consent document will be randomized to a placebo group or doxycycline group
- Participants randomized to the doxycycline group will take doxycycline 100 mg twice daily for 8 weeks.
- Participants randomized to the placebo group will take placebo that will look identical to the study medication twice daily for the duration of the 8-week study period.
- There will be online surveys performed at the start of the study, after 4 weeks, and after 8 weeks.
- Participation in this study is expected to last 8 weeks and will be performed virtually, with no in-person appointments required
- The recruitment goal is 128 participants

Eligibility

Participants will be recruited based on the following criteria:

- Live in Missouri or Illinois
- Patients 18-70 years of age
- Patients diagnosed with HHT with the Curacao criteria or positive blood DNA test.
- Moderate or Severe nosebleeds
- Participants not participating in other clinical trials.
- Females of childbearing age who are sexually active must agree to remain on at least one form of contraception during the study period and 28 days after completion of the study medication.
- Participants must have internet access for completion of online questionnaires and surveys
- Participants will be excluded if they have an allergy to doxycycline, have taken a medication that is contraindicated with doxycycline (penicillin, isotretinoin, benzodiazepines, and warfarin).

Will I be paid for participation in this study?

- Yes, participants will be paid $80 for completing all study requirements.

Are there any costs to study participation?

- There will be no costs to study participation, all medications will be paid for by the study team.

How can I enroll in this trial?

HHT patients with moderate to severe nosebleeds should contact **Firas Hentati** at **otooutcomes@wustl.edu** (please put HHT study in the subject) or by phone **314-362-9475**